ストックスクリーナーアプリを入手
9.02
9.07%
0.75
前日終値:
$8.27
開ける：
$8.29
24時間の取引高:
587.07K
Relative Volume:
5.03
時価総額：
$84.44M
収益：
$24.99M
当期純損益:
$-108.83M
株価収益率:
-0.6002
EPS:
-15.0286
ネットキャッシュフロー:
$-91.62M
1週間 パフォーマンス:
-1.74%
1か月 パフォーマンス:
+0.22%
6か月 パフォーマンス:
+32.45%
1年 パフォーマンス:
-32.79%
1日の値動き範囲:
$8.29
$9.11
1週間の範囲:
$7.89
$9.44
52週間の値動き範囲:
$6.01
$17.44
Adicet Bio Inc Stock (ACET) Company Profile
Compare ACET vs VRTX, REGN, MRNA, ARGX, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ACET
Adicet Bio Inc
|
9.02 | 84.44M | 24.99M | -108.83M | -91.62M | -15.03 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Adicet Bio Inc Stock (ACET) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-09-30 | 再開されました | Guggenheim | Buy |
| 2024-09-11 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2023-06-27 | ダウングレード | Guggenheim | Buy → Neutral |
| 2023-06-27 | ダウングレード | JMP Securities | Mkt Outperform → Mkt Perform |
| 2023-06-01 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2022-09-21 | 開始されました | JP Morgan | Overweight |
| 2022-03-31 | 開始されました | SMBC Nikko | Outperform |
| 2022-03-08 | 開始されました | Truist | Buy |
| 2022-03-04 | 開始されました | Jefferies | Buy |
| 2021-05-18 | 開始されました | BTIG Research | Buy |
| 2021-04-23 | 開始されました | H.C. Wainwright | Buy |
| 2021-04-14 | 開始されました | Canaccord Genuity | Buy |
| 2021-04-08 | 開始されました | Guggenheim | Buy |
| 2020-11-04 | 開始されました | B. Riley Securities | Buy |
| 2020-10-27 | 開始されました | JMP Securities | Mkt Outperform |
| 2020-10-16 | 開始されました | Wedbush | Outperform |
すべてを表示
Adicet Bio Inc (ACET) 最新ニュース
Adicet Bio (NASDAQ:ACET) Shares Break Above 200-Day Moving AverageShould You Sell? - MarketBeat
Adicet Bio (NASDAQ:ACET) Stock Moved Up to "Hold" by Wall Street Zen - MarketBeat
Data on a possible lupus treatment are due Monday - Stock Titan
H.C. Wainwright reiterates Adicet Bio stock rating on data update By Investing.com - Investing.com Nigeria
H.C. Wainwright reiterates Adicet Bio stock rating on data update - Investing.com
HC Wainwright Reiterates Buy Rating for Adicet Bio (NASDAQ:ACET) - MarketBeat
HC Wainwright & Co. reiterates Buy rating on Adicet Bio, $27 price target - TradingView
Adicet Bio, Inc. (NASDAQ:ACET) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Adicet Bio (ACET): The Countdown To Prula-cel Data - RTTNews
Adicet Bio (NASDAQ:ACET) Stock Passes Above Two Hundred Day Moving AverageTime to Sell? - MarketBeat
Adicet Bio Highlights Prula-cel Autoimmune CAR-T Pipeline Progress - TipRanks
Adicet Bio posts September 2026 investor presentation outlining prula-cel and ADI-212 clinical timelines - TradingView
Adicet Bio Stock Price Forecast. Should You Buy ACET? - StockInvest.us
Wall Street Analysts See a 258.21% Upside in Adicet Bio (ACET): Can the Stock Really Move This High? - Yahoo Finance
Is Adicet Bio (ACET) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Adicet Bio (NASDAQ:ACET) Upgraded to Strong-Buy at Jefferies Financial Group - marketbeat.com
A biotech CEO will speak in New York Sept. 15. Audio will be online. - Stock Titan
Adicet Bio to Participate in Fireside Chat at H.C. Wainwright 28th Annual Global Investment Conference - Yahoo Finance
Adicet Bio (NASDAQ: ACET) Advances ADI-212 Clinical Trial for mCRPC and Prepares Prula-Cel Data Release - Kalkine Media
Adicet Bio (NASDAQ: ACET) Advances ADI-212 Clinical Trial for mCRPC, Prula-cel Data Expected in September 2026 - Kalkine Media
Adicet Bio, Inc. (NASDAQ:ACET) Sees Large Drop in Short Interest - MarketBeat
Adicet Bio advances CAR-T programs and clinical pipeline - grafa.com
Adicet Bio completes prula-cel Phase 1 SLE analysis - TipRanks
Adicet Bio says prula-cel last patient visit complete; topline data due Sept 2026, ADI-212 IND cleared - TradingView
The final patient visit is complete in a lupus cell-therapy study. Adicet Bio expects results from 22 patients in September. - stocktitan.net
Adicet Bio grants a new hire options on 1,500 shares over four years - Stock Titan
Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
ACET Q2 2026 Earnings: Narrower Loss Beats Expectations as Pipeline AdvancesReturn On Capital - dars.gov.et
Press Release Service: Adicet Bio Announces FDA Clearance of IND Application for ADI-212 - CRISPR Medicine News
Adicet Bio Gets FDA Clearance for IND for ADI-212 in prostate cancer - marketscreener.com
Adicet Bio receives FDA clearance for prostate cancer trial By Investing.com - Investing.com Canada
Adicet Bio receives FDA clearance for prostate cancer trial - Investing.com India
Zacks Investment Research - גלובס
Adicet (ACET) Trading: Adds 0.32% to Close at $9.41 in the Current Update; Key Range - vinanet.vn
ETFs Investing in Adicet Bio Inc Stocks - TradingView
Are Medical Stocks Lagging Adicet Bio (ACET) This Year? - Eastern Progress
ACET Q2 2026 Earnings: Narrower-Than-Expected Loss of $1.99 Per Share Buoys SharesSegment Revenue Breakdown - vinanet.vn
RA Capital discloses 9.99% Adicet Bio (ACET) stake with warrant blocker - Stock Titan
Adicet Bio (ACET) - Zacks Investment Research
Adicet Bio: A Cheap Gamma Delta T-Cell Play (NASDAQ:ACET) - Seeking Alpha
Wall Street Analysts Think Adicet Bio (ACET) Could Surge 301.57%: Read This Before Placing a Bet - Zacks Investment Research
Adicet Bio (ACET) Edges Higher to $8.26 as Biotech Stock Consolidates Between Key LevelsETF Flow - Vinanet
HC Wainwright Has Strong Estimate for Adicet Bio Q3 Earnings - MarketBeat
Adicet Bio at Canaccord Genuity: lupus data drives next step By Investing.com - Investing.com Canada
Adicet Bio Eyes Key Lupus Data This Quarter for Off-the-Shelf Cell Therapy - MarketBeat
All You Need to Know About Adicet Bio (ACET) Rating Upgrade to Buy - newsbreak.com
H.C. Wainwright Maintains Adicet Bio(ACET.US) With Buy Rating, Maintains Target Price $27 - Moomoo
JonesTrading Maintains Adicet Bio(ACET.US) With Buy Rating, Maintains Target Price $20 - Moomoo
Price to sales forward of Adicet Bio, Inc. – NASDAQ:ACET - TradingView
Adicet Bio Inc (ACET) Earnings Forecast: Future EPS & Revenue Growth Estimates - tradingkey.com
Press Release Service: Adicet Bio Reports Second Quarter 2026 Financial Results and Provides Business Updates - CRISPR Medicine News
Adicet Bio Inc (ACET) 財務データ
収益
当期純利益
現金流量
EPS
Adicet Bio Inc (ACET) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 10% Owner |
Feb 19 '26 |
Buy |
7.21 |
74,268 |
535,472 |
1,107,873 |
| RA CAPITAL MANAGEMENT, L.P. | 10% Owner |
Feb 18 '26 |
Buy |
7.04 |
74,577 |
525,022 |
1,033,605 |
| ORBIMED ADVISORS LLC | 10% Owner |
Apr 08 '26 |
Sale |
6.42 |
72,939 |
468,082 |
0 |
| ORBIMED ADVISORS LLC | 10% Owner |
Apr 07 '26 |
Sale |
6.52 |
31,719 |
206,765 |
32,523 |
3.06%
2.55%
大文字化:
|
ボリューム (24 時間):